Tumor Treating Fields Significantly Delay Intracranial Progression in NSCLC Patients Following Stereotactic Radiosurgery: Results of the METIS Trial
Posted innews Oncology Radiology

Tumor Treating Fields Significantly Delay Intracranial Progression in NSCLC Patients Following Stereotactic Radiosurgery: Results of the METIS Trial

The Phase 3 METIS trial demonstrates that Tumor Treating Fields (TTFields) following stereotactic radiosurgery significantly prolongs time to intracranial progression in NSCLC patients with brain metastases, without compromising neurocognitive function or quality of life, offering a promising new treatment paradigm.
Bevacizumab and Fractionated Stereotactic Radiotherapy: A Synergistic Breakthrough for Extensive Brain Metastases in NSCLC
Posted innews Oncology Radiology

Bevacizumab and Fractionated Stereotactic Radiotherapy: A Synergistic Breakthrough for Extensive Brain Metastases in NSCLC

The GASTO-1053 phase II study demonstrates that combining bevacizumab with fractionated stereotactic radiotherapy significantly improves intracranial progression-free survival (18.3 months) and quality of life for NSCLC patients with extensive brain metastases, providing a safe, effective alternative to whole-brain radiotherapy.
Preoperative versus Postoperative Stereotactic Radiation Therapy for Brain Metastases: Safety, Feasibility, and Efficiency Insights from a Phase 3 Randomized Trial
Posted inClinical Updates General Surgery Oncology Radiology Specialties

Preoperative versus Postoperative Stereotactic Radiation Therapy for Brain Metastases: Safety, Feasibility, and Efficiency Insights from a Phase 3 Randomized Trial

A phase 3 randomized trial demonstrates that preoperative stereotactic radiation therapy (SRT) for brain metastases offers comparable safety and reduced treatment duration compared to postoperative SRT, potentially improving patient care logistics.